# A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

> **NCT06109649** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Clinuvel, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Afamelanotide and NB-UVB Light
- **PROCEDURE:** NB-UVB Light

## Key facts

- **NCT ID:** NCT06109649
- **Lead sponsor:** Clinuvel, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-11
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109649, "A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06109649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*